Vimta Labs reports strong profit growth, boosted by bonus share issue

Vimta Labs Limited reported a profit of INR 388.13 million for the half year ended September 30, 2025, from continuing operations, a substantial increase from INR 309.20 million in the previous year. Total income for the half year reached INR 2,038.19 million, up from INR 1,609.93 million in the prior period. For the quarter ended September 30, 2025, profit from continuing operations was INR 188.93 million on a total income of INR 993.13 million.

Basic earnings per share (EPS) from continuing operations for the half year stood at INR 8.71, compared to INR 6.97 previously. The company's total assets as of September 30, 2025, were INR 5,181.55 million, with equity share capital at INR 89.08 million. The board of directors approved these unaudited results at their meeting on November 3, 2025.

Additionally, Vimta Labs noted the issue of bonus shares in a 1:1 ratio, following shareholder approval on June 6, 2025, resulting in 2,22,52,784 equity shares being allotted. The company also disclosed details of its discontinued diagnostic and pathological services business, which was sold in October 2024 for INR 70 million.